MARKET

LTRN

LTRN

Lantern Pharma Inc
NASDAQ
1.120
-0.970
-46.41%
After Hours: 1.280 +0.16 +14.29% 19:59 03/27 EDT
OPEN
2.230
PREV CLOSE
2.090
HIGH
2.400
LOW
1.110
VOLUME
7.44M
TURNOVER
--
52 WEEK HIGH
5.74
52 WEEK LOW
1.110
MARKET CAP
12.53M
P/E (TTM)
-0.6390
1D
5D
1M
3M
1Y
5Y
1D
BRIEF-Lantern Pharma Confirms Panna Sharma Continues To Serve As President And CEO Alerts Investors To False Third-Party Report
Reuters · 1d ago
Lantern Pharma says CEO Panna Sharma remains in role; company warns investors about false third-party report
Reuters · 1d ago
BUZZ-U.S. STOCKS ON THE MOVE-Entergy, IDEX Corp, Quanta Services
Reuters · 1d ago
Lantern Pharma Stock Falls 10% After FDA Clears Investigational New Drug Application For STAR-001
NASDAQ · 1d ago
BUZZ-U.S. STOCKS ON THE MOVE-Alphabet, Phathom, Argan
Reuters · 1d ago
BUZZ-Lantern Pharma up after FDA allows trial of pediatric brain cancer drug
Reuters · 1d ago
LANTERN PHARMA SHARES UP 11.5% PREMARKET AFTER RECEIVING FDA CLEARANCE TO START CHILD BRAIN CANCER TREATMENT STUDY
Reuters · 1d ago
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 1d ago
More
About LTRN
Lantern Pharma Inc. is an artificial intelligence (AI) company. The Company is developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 100 billion oncology-focused data points and a library of over 200+ advanced ML algorithms to help solve problems in oncology drug development. It is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. It has active clinical programs for its three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple cancer indications, including both solid tumors and blood cancers. It is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.

Webull offers Lantern Pharma Inc stock information, including NASDAQ: LTRN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LTRN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LTRN stock methods without spending real money on the virtual paper trading platform.